Source: CNN Politics

CNN Politics reports that the U.S. Food and Drug Administration (FDA) is advancing the use of artificial intelligence in drug regulation through its new ELSA initiative. The program aims to integrate AI tools to enhance the efficiency and accuracy of drug approval and safety monitoring processes.

Experts highlight the potential benefits of AI in accelerating innovation while maintaining patient safety. The FDA’s approach reflects a broader trend of incorporating advanced technologies into healthcare regulation. However, challenges remain in ensuring transparency, accountability, and ethical considerations in AI-driven drug evaluation. Stakeholders emphasize the need for clear regulatory frameworks to guide AI use in pharmaceutical oversight.